|
|
|
| |
STAR (Study of Tamoxifen and Raloxifene)
Contact Us
Regional Cancer Center: Research
360.514.2155
|
 |
Called the Study of Tamoxifen and Raloxifene, or STAR, this trial is sponsored by the National Surgical Adjuvant Breast and Bowel Project (NSABP), which conducted the first breast cancer prevention trial with Tamoxifen and demonstrated a 49% reduction in breast cancer in women at increased risk.
The STAR study will compare Tamoxifen with Raloxifene, a new drug which is felt from early clinical trials to have a similar breast cancer prevention benefit. Additional potential benefits may include reduced risk of osteoporosis and lowering of cholesterol.
|
Who Can Participate?
If you are or someone you know is a postmenopausal woman with two of the following risk factors you may be able to take part in this important research if:
- You have a close family member with breast cancer.
- You have had a breast biopsy.
- You are 35 years of age or older.
To learn more, please call 503.216.6260, or toll free 800.677.6752 ext. 66260. Or you may contact us by email at: ejohnson2@providence.org. You may also send email to bgetman@swmedicalcenter.org.
The Columbia River Oncology Program is made up of physicians, nurses, and staff at PeaceHealth Southwest Medical Center, Legacy Emanuel Hospital, Legacy Good Samaritan Hospital, Legacy Meridian Park Hospital, Legacy Mt. Hood Hospital, Providence Milwaukie Hospital, Providence Portland Medical Center, and Providence St. Vincent Medical Center.
Back to Finding the Cure Main Page |
|
|
|
